New Delhi: The government has announced mandatory product testing for all cough syrup exporters by a specified government lab from June 1. This announcement comes in the wake of concerns over the quality of cough syrup being imported from India. The government has specified labs for this purpose which include the Indian Pharmacopoeia Commission, regional drug testing lab (RDTL – Chandigarh), central drugs lab (CDL – Kolkata), central drug testing lab (CDTL – Chennai Hyderabad, Mumbai), RDTL (Guwahati)] and the NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited drug testing labs of state governments.
“The export of cough syrup shall be permitted to be exported subject to export samples being tested and production of a certificate of analysis issued by any of the laboratories…, with effect from June 1, 2023,” the Directorate General of Foreign Trade (DGFT) said in a notification on Monday.
The decision is aimed at re-emphasizing India’s commitment towards assuring the quality of various pharmaceutical products exported from India, a government official told PTI.
The central government has decided to initiate a process of a pre-quality check of the cough syrup formulations being exported, the official added.
For the unversed, In February, the Tamil Nadu-based Global Pharma Healthcare recalled its entire lot of eye drops. Earlier, cough syrup exported from India was also linked to the deaths of 66 and 18 children in Gambia and Uzbekistan, respectively.
It is noteworthy here that the Indian pharmaceutical industry is a prominent manufacturer and exporter of medical products to the entire globe; ranging from highly developed countries to the LMIC (low and middle-income countries).
Globally, India ranks third in terms of pharmaceutical production by volume and 14th by value.
Retired bank official arrested for stalking, molesting woman at kolkatta metro station